ALX Oncology Holdings Inc. (ALXO) Presents at UBS Global Biopharma Conference 2026 Transcript

ALX Oncology remains a pre-revenue clinical-stage biotech, with no reported revenue across the ten quarters analyzed and quarterly R&D cut from $34.7M in 2024Q2 to $13.1M in 2026Q2, a reduction of roughly 62 percent that has narrowed the operating loss from -$41.5M to -$18.0M.
Price trend, volume and key moving averages
Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 16, 2026 | -$0.15+0.0% vs -$0.15 | — vs — |
Q3 2026 Aug 6, 2026 | -$0.13+9.0% vs -$0.14 | — vs — |
Q2 2026 May 8, 2026 | -$0.17-13.3% vs -$0.15 | — vs — |
Q1 2026 Feb 27, 2026 | -$0.42-10.5% vs -$0.38 | — vs — |
ALX Oncology Holdings Inc. (ALXO) Presents at UBS Global Biopharma Conference 2026 Transcript

Expect to report safety and early efficacy data from the Phase 1 dose-escalation study of ALX2004 in EGFR-expressing solid tumors and plan to host a KOL webinar to review the results in December 2026 Topline data from 120 patients in Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer expected in 2H 2027 SOUTH SAN FRANCISCO, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that ALX Oncology leadership will participate in fireside chats at three upcoming investor conferences.
Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained HER2-positive disease

Benchmark ALXO against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for ALX Oncology Holdings Inc. (ALXO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.97 | $130.54M | -1.70 | — | — | -73.35% | — | |
| $1.05 | $122.39M | -1.04 | -51.24% | -2619.64% | -73.92% | — | |
| $33.17 | $6.85B | -13.47 | — | -7173.52% | -63.01% | — | |
| $15.76 | $1.98B | -4.51 | -4.26% | -445% | -90.04% | — | |
| $6.40 | $266.51M | 18.97 | 10.37% | 20.98% | — | — | |
| $34.42 | $1.18B | -6.64 | -43.89% | -339.67% | -29.31% | — |
ALX Oncology Holdings Inc. (ALXO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
ALX Oncology Holdings Inc. (ALXO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 30, 2026·SEC
Jun 26, 2026·SEC
Get notified when ALXO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ALX Oncology Holdings Inc. (ALXO) stock FAQ — growth, dividends, profitability & financials explained
No. ALX Oncology Holdings Inc. (ALXO) reported a net loss of $80.6M over the trailing twelve months.
ALX Oncology Holdings Inc. (ALXO) had a return on equity (ROE) of -73.4% over the trailing twelve months. A negative ROE means the company lost money over the period.
ALX Oncology Holdings Inc. (ALXO) had negative free cash flow of $68.6M over the trailing twelve months.